SCHEMBL1765050

SCHEMBL1765050

CCOC(=O)c1cc(-c2cc(F)cc(C(F)(F)F)c2)n(-c2ccc(F)c(Cl)c2)n1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRNA7 P36544 3/20 0.50
FAAH O00519 3/20 0.46
CA9 Q16790 3/20 0.45
RXRA P19793 1/20 0.43
RXRB P28702 1/20 0.43
RXRG P48443 1/20 0.43
RXFP1 Q9HBX9 1/20 0.42
MGLL Q99685 1/20 0.42
RPA1 P27694 2/20 0.41
GABRA2 P47869 3/20 0.40
GABRB2 P47870 3/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
ATM Q13315 1/20 0.40
GABRP O00591 1/20 0.40
GABRD O14764 1/20 0.40
GABRA1 P14867 1/20 0.40
GABRB1 P18505 1/20 0.40
GABRG2 P18507 1/20 0.40
GABRB3 P28472 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1765268 0.90 LMNA (0.49) CHRNA7FAAHCA9MGLLGABRA2
SCHEMBL1526084 0.89 CHRNA7 (0.54) CHRNA7FAAHCA9RXRARXRB
SCHEMBL1764943 0.89 FAAH (0.53) CHRNA7FAAHCA9RXFP1MGLL
SCHEMBL1764884 0.89 CHRNA7 (0.53) CHRNA7FAAHCA9RXFP1MGLL
SCHEMBL1765484 0.87 CHRNA7 (0.52) CHRNA7FAAHCA9RXFP1MGLL
SCHEMBL1764893 0.86 CHRNA7 (0.51) CHRNA7FAAHCA9RXFP1MGLL
SCHEMBL1765411 0.85 RPA1 (0.56) RXRARXRBRXRGRPA1MEN1
SCHEMBL1765031 0.85 CHRNA7 (0.60) CHRNA7FAAHCA9RXFP1MGLL
SCHEMBL1764980 0.85 CHRNA7 (0.53) CHRNA7FAAHCA9RXFP1MGLL
SCHEMBL1765054 0.84 CHRNA7 (0.49) CHRNA7FAAHCA9RXFP1MGLL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8399682-B2 Substituted (pyrazolylcarbonyl)imidazolidinones and their use AICURIS GMBH & CO. KG (DE) 2013-03-19 US disclosed
US-8399682-B2 Substituted (pyrazolylcarbonyl)imidazolidinones and their use AICURIS GMBH & CO. KG (DE) 2013-03-19 US disclosed
US-8399682-B2 Substituted (pyrazolylcarbonyl)imidazolidinones and their use AICURIS GMBH & CO. KG (DE) 2013-03-19 US disclosed
US-20110124618-A1 SUBSTITUTED (PYRAZOLYLCARBONYL)IMIDAZOLIDINONES AND THEIR USE AICURIS GMBH & CO. KG (DE) 2011-05-26 US disclosed
US-20110124618-A1 SUBSTITUTED (PYRAZOLYLCARBONYL)IMIDAZOLIDINONES AND THEIR USE AICURIS GMBH & CO. KG (DE) 2011-05-26 US disclosed
US-20110124618-A1 SUBSTITUTED (PYRAZOLYLCARBONYL)IMIDAZOLIDINONES AND THEIR USE AICURIS GMBH & CO. KG (DE) 2011-05-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110124618-A1 SUBSTITUTED (PYRAZOLYLCARBONYL)IMIDAZOLIDINONES AND THEIR USE TPMT, PAICS, THPO CHRNA7 3365/4885FAAH 4725/4885CA9 4825/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.